

1 FILING DATE: 06-JUN-1996
 2 CLASSIFICATION: 445
 3 ATTORNEY/AGENT INFORMATION:
 4 NAME: Park, Fredrick R.
 5 REGISTRATION NUMBER: 35,646
 6 REFERENCE/AGENT NUMBER: 25,771 20941,130
 7 TELECOMMUNICATION INFORMATION:
 8 TELEPHONE: (415) 814-5600
 9 TELEFAX: (415) 494-0792
 10 TELEFAX: 706141
 11 INFORMATION FOR SEQ ID NO: 21:
 12 SEQUENCE CHARACTERISTICS:
 13 LENGTH: 9 amino acids
 14 TYPE: amino acid
 15 STRANDNESS: single
 16 TOPOLOGY: linear
 17 IMMEDIATE SOURCE:
 18 LIBRARY: xyz (details p4, 16)
 19 CLONE: 3E11
 20 US-08-600-092-21

Query Match 100.0% Score 194 H 4 L 0 length 9
 Best Local Similarity 100.0% Prod. No. 117-01
 Matches 4 Conservative 0 Mismatched 0 Indels 0 Gaps 0
 QY 1 HIRG 4
 ID 4 HIRG 7

RESULT 5
 US-08-416-970-3
 1 Sequence 3, Application US/09416950
 2 Patent No. 5780036
 3 GENERAL INFORMATION:
 4 APPLICANT: CHISARI, FRANCIS V.
 5 TITLE OF INVENTION: PEPTIDES FOR IMMUNITING ANIMALS
 6 TITLE OF INVENTION: PEPTIDES FOR IMMUNITING ANIMALS
 7 NUMBER OF SEQUENCES: 11
 8 CORRESPONDING ADDRESS:
 9 ADDRESS: Two Second and Townsend Streets, San Francisco, CA 94105-1492
 10 STREET: One Market Place, Street, San Francisco, CA 94105-1492
 11 CITY: San Francisco
 12 STATE: CA
 13 COUNTRY: U.S.A.
 14 ZIP: 94105-1492
 15 COMPUTER READABLE FORM:
 16 MEDIUM TYPE: Floppy disk
 17 COMPUTER: IBM PC compatible
 18 OPERATING SYSTEM: PC DOS 3.31
 19 SOFTWARE: Patent Release #100, Vol. 1, 1996
 20 CURRENT APPLICATION DATA:
 21 APPLICATION NUMBER: 09/09416950
 22 FILING DATE: 06/06/96
 23 CLASSIFICATION: 424
 24 PRIOR APPLICATION DATA:
 25 APPLICATION NUMBER: 09/09416950
 26 FILING DATE: 06/06/96
 27 APPLICATION NUMBER: 09/09416950
 28 FILING DATE: 06/06/96
 29 PRIOR APPLICATION DATA:
 30 APPLICATION NUMBER: 09/09416950
 31 FILING DATE: 06/06/96
 32 FILING DATE: 06/06/96
 33 FILING DATE: 06/06/96
 34 FILING DATE: 06/06/96
 35 FILING DATE: 06/06/96
 36 FILING DATE: 06/06/96
 37 FILING DATE: 06/06/96
 38 FILING DATE: 06/06/96
 39 FILING DATE: 06/06/96
 40 FILING DATE: 06/06/96
 41 FILING DATE: 06/06/96
 42 FILING DATE: 06/06/96
 43 FILING DATE: 06/06/96
 44 FILING DATE: 06/06/96
 45 FILING DATE: 06/06/96
 46 FILING DATE: 06/06/96
 47 FILING DATE: 06/06/96
 48 FILING DATE: 06/06/96
 49 FILING DATE: 06/06/96
 50 FILING DATE: 06/06/96
 51 FILING DATE: 06/06/96
 52 FILING DATE: 06/06/96
 53 FILING DATE: 06/06/96
 54 FILING DATE: 06/06/96
 55 FILING DATE: 06/06/96
 56 FILING DATE: 06/06/96
 57 FILING DATE: 06/06/96
 58 FILING DATE: 06/06/96
 59 FILING DATE: 06/06/96
 60 FILING DATE: 06/06/96
 61 FILING DATE: 06/06/96
 62 FILING DATE: 06/06/96
 63 FILING DATE: 06/06/96
 64 FILING DATE: 06/06/96
 65 FILING DATE: 06/06/96
 66 FILING DATE: 06/06/96
 67 FILING DATE: 06/06/96
 68 FILING DATE: 06/06/96
 69 FILING DATE: 06/06/96
 70 FILING DATE: 06/06/96
 71 FILING DATE: 06/06/96
 72 FILING DATE: 06/06/96
 73 FILING DATE: 06/06/96
 74 FILING DATE: 06/06/96
 75 FILING DATE: 06/06/96
 76 FILING DATE: 06/06/96
 77 FILING DATE: 06/06/96
 78 FILING DATE: 06/06/96
 79 FILING DATE: 06/06/96
 80 FILING DATE: 06/06/96
 81 FILING DATE: 06/06/96
 82 FILING DATE: 06/06/96
 83 FILING DATE: 06/06/96
 84 FILING DATE: 06/06/96
 85 FILING DATE: 06/06/96
 86 FILING DATE: 06/06/96
 87 FILING DATE: 06/06/96
 88 FILING DATE: 06/06/96
 89 FILING DATE: 06/06/96
 90 FILING DATE: 06/06/96
 91 FILING DATE: 06/06/96
 92 FILING DATE: 06/06/96
 93 FILING DATE: 06/06/96
 94 FILING DATE: 06/06/96
 95 FILING DATE: 06/06/96
 96 FILING DATE: 06/06/96
 97 FILING DATE: 06/06/96
 98 FILING DATE: 06/06/96
 99 FILING DATE: 06/06/96
 100 FILING DATE: 06/06/96

1 LENGTH: 10 amino acids
 2 TYPE: amino acid
 3 STRANDNESS: single
 4 TOPOLOGY: linear
 5 IMMEDIATE SOURCE:
 6 LIBRARY: xyz (details p4, 16)
 7 CLONE: 3E11
 8 US-08-416-970-3

Query Match 100.0% Score 194 H 4 L 0 length 9
 Best Local Similarity 100.0% Prod. No. 117-01
 Matches 4 Conservative 0 Mismatched 0 Indels 0 Gaps 0
 QY 1 HIRG 4
 ID 4 HIRG 7

RESULT 5
 US-08-416-970-3
 1 Sequence 3, Application US/09416950
 2 Patent No. 5780036
 3 GENERAL INFORMATION:
 4 APPLICANT: CHISARI, FRANCIS V.
 5 TITLE OF INVENTION: PEPTIDES FOR IMMUNITING ANIMALS
 6 TITLE OF INVENTION: PEPTIDES FOR IMMUNITING ANIMALS
 7 NUMBER OF SEQUENCES: 11
 8 CORRESPONDING ADDRESS:
 9 ADDRESS: Two Second and Townsend Streets, San Francisco, CA 94105-1492
 10 STREET: One Market Place, Street, San Francisco, CA 94105-1492
 11 CITY: San Francisco
 12 STATE: CA
 13 COUNTRY: U.S.A.
 14 ZIP: 94105-1492
 15 COMPUTER READABLE FORM:
 16 MEDIUM TYPE: Floppy disk
 17 COMPUTER: IBM PC compatible
 18 OPERATING SYSTEM: PC DOS 3.31
 19 SOFTWARE: Patent Release #100, Vol. 1, 1996
 20 CURRENT APPLICATION DATA:
 21 APPLICATION NUMBER: 09/09416950
 22 FILING DATE: 06/06/96
 23 CLASSIFICATION: 424
 24 PRIOR APPLICATION DATA:
 25 APPLICATION NUMBER: 09/09416950
 26 FILING DATE: 06/06/96
 27 APPLICATION NUMBER: 09/09416950
 28 FILING DATE: 06/06/96
 29 PRIOR APPLICATION DATA:
 30 APPLICATION NUMBER: 09/09416950
 31 FILING DATE: 06/06/96
 32 FILING DATE: 06/06/96
 33 FILING DATE: 06/06/96
 34 FILING DATE: 06/06/96
 35 FILING DATE: 06/06/96
 36 FILING DATE: 06/06/96
 37 FILING DATE: 06/06/96
 38 FILING DATE: 06/06/96
 39 FILING DATE: 06/06/96
 40 FILING DATE: 06/06/96
 41 FILING DATE: 06/06/96
 42 FILING DATE: 06/06/96
 43 FILING DATE: 06/06/96
 44 FILING DATE: 06/06/96
 45 FILING DATE: 06/06/96
 46 FILING DATE: 06/06/96
 47 FILING DATE: 06/06/96
 48 FILING DATE: 06/06/96
 49 FILING DATE: 06/06/96
 50 FILING DATE: 06/06/96
 51 FILING DATE: 06/06/96
 52 FILING DATE: 06/06/96
 53 FILING DATE: 06/06/96
 54 FILING DATE: 06/06/96
 55 FILING DATE: 06/06/96
 56 FILING DATE: 06/06/96
 57 FILING DATE: 06/06/96
 58 FILING DATE: 06/06/96
 59 FILING DATE: 06/06/96
 60 FILING DATE: 06/06/96
 61 FILING DATE: 06/06/96
 62 FILING DATE: 06/06/96
 63 FILING DATE: 06/06/96
 64 FILING DATE: 06/06/96
 65 FILING DATE: 06/06/96
 66 FILING DATE: 06/06/96
 67 FILING DATE: 06/06/96
 68 FILING DATE: 06/06/96
 69 FILING DATE: 06/06/96
 70 FILING DATE: 06/06/96
 71 FILING DATE: 06/06/96
 72 FILING DATE: 06/06/96
 73 FILING DATE: 06/06/96
 74 FILING DATE: 06/06/96
 75 FILING DATE: 06/06/96
 76 FILING DATE: 06/06/96
 77 FILING DATE: 06/06/96
 78 FILING DATE: 06/06/96
 79 FILING DATE: 06/06/96
 80 FILING DATE: 06/06/96
 81 FILING DATE: 06/06/96
 82 FILING DATE: 06/06/96
 83 FILING DATE: 06/06/96
 84 FILING DATE: 06/06/96
 85 FILING DATE: 06/06/96
 86 FILING DATE: 06/06/96
 87 FILING DATE: 06/06/96
 88 FILING DATE: 06/06/96
 89 FILING DATE: 06/06/96
 90 FILING DATE: 06/06/96
 91 FILING DATE: 06/06/96
 92 FILING DATE: 06/06/96
 93 FILING DATE: 06/06/96
 94 FILING DATE: 06/06/96
 95 FILING DATE: 06/06/96
 96 FILING DATE: 06/06/96
 97 FILING DATE: 06/06/96
 98 FILING DATE: 06/06/96
 99 FILING DATE: 06/06/96
 100 FILING DATE: 06/06/96

1 MEDIUM TYPE: floppy disk
 2 COMPUTER: IBM PC compatible
 3 OPERATING SYSTEM: MS-DOS/MS-TPS
 4 SOFTWARE: Patent Release #1.0, Ver 4.1
 5 CURRENT APPLICATION DATA:
 6 APPLICATION NUMBER: 02/06/794,643
 7 FILING DATE: 11-09-1996
 8 CLASSIFICATION: 514
 9 ATTORNEY/AGENT INFORMATION:
 10 NAME: Hubert, Robert L.
 11 REGISTRATION NUMBER: 36,592
 12 REFERENCE/BOOKLET NUMBER: 184281
 13 TELECOMMUNICATION INFORMATION:
 14 TELEPHONE: 919-248-1000
 15 INFORMATION FOR SEQ ID NO: 149:
 16 SEQUENCE CHARACTERISTICS:
 17 LENGTH: 18 amino acids
 18 TYPE: amino acid
 19 STRANDEDNESS:
 20 TOPOLOGY: linear
 21 MOLECULE TYPE: peptide
 22 DS-08-864-49A-149

Query Match: 100.0% Score 19; Length 18
 Best Local Similarity: 100.0% Pred. No. of
 Matches: 4; Conservative 0; Mismatch 8; Gaps 0

VY 1 118G 4
 1111
 DB 11 118G 14

1 RESULT 1:
 2 DS-08-864-49A-107
 3 Sequence: 107, Application No/Seq#49A
 4 Patent No.: 5015545
 5 GENERAL INFORMATION:
 6 APPLICANT: Huse, Timothy M.
 7 APPLICANT: Huse, Mark L.
 8 APPLICANT: Strand, Kurt
 9 TITLE OF INVENTION: GLOBULIN B-CELL T-CELL
 10 MEMBER OF SEQUENCES: 111
 11 ADDRESS: 4000 S. Richardson P.O.
 12 STREET: 4000 S. Richardson P.O.
 13 CITY: La Jolla
 14 STATE: CA
 15 COUNTRY: USA
 16 ZID: 92037
 17 COMPUTER READABLE FORM:
 18 MEDIUM TYPE: floppy disk
 19 COMPUTER: IBM PC compatible
 20 OPERATING SYSTEM: PC-TOS/MS-TPS
 21 SOFTWARE: Patent Release #1.0, Ver 4.1
 22 CURRENT APPLICATION DATA:
 23 APPLICATION NUMBER: 02/06/794,643
 24 FILING DATE: February 21, 1997
 25 CLASSIFICATION: 424
 26 ATTORNEY/AGENT INFORMATION:
 27 NAME: Huse, Lisa A.
 28 REGISTRATION NUMBER: 48,847
 29 REFERENCE/BOOKLET NUMBER: 184281
 30 TELECOMMUNICATION INFORMATION:
 31 TELEPHONE: (619) 678-5070
 32 TELEFAX: (619) 678-5099
 33 TELEX:
 34 INFORMATION FOR SEQ ID NO: 107:
 35 SEQUENCE CHARACTERISTICS:
 36 LENGTH: 18 amino acids
 37 TYPE: amino acid
 38 STRANDEDNESS: single

1 Topology: linear
 2 DS-08-864-49A-107
 3 Query Match: 100.0% Score 19; Length 18
 4 Best Local Similarity: 100.0% Pred. No. of
 5 Matches: 4; Conservative 0; Mismatch 8; Gaps 0

VY 1 118G 4
 1111
 DB 5 118G 8

1 RESULT 1:
 2 DS-08-974-225-149
 3 Sequence: 149, Application No/Seq#225
 4 Patent No.: 6085018
 5 GENERAL INFORMATION:
 6 APPLICANT: Hubert, Robert L.
 7 APPLICANT: Hubert, Mark L.
 8 APPLICANT: Hubert, Kurt
 9 TITLE OF INVENTION: GLOBULIN B-CELL T-CELL
 10 MEMBER OF SEQUENCES: 111
 11 ADDRESS: 4000 S. Richardson P.O.
 12 STREET: 4000 S. Richardson P.O.
 13 CITY: La Jolla
 14 STATE: CA
 15 COUNTRY: USA
 16 ZID: 27109
 17 COMPUTER READABLE FORM:
 18 MEDIUM TYPE: floppy disk
 19 COMPUTER: IBM PC compatible
 20 OPERATING SYSTEM: PC-TOS/MS-TPS
 21 SOFTWARE: Patent Release #1.0, Ver 4.1
 22 CURRENT APPLICATION DATA:
 23 APPLICATION NUMBER: 02/06/794,643
 24 FILING DATE: February 21, 1997
 25 CLASSIFICATION: 424
 26 ATTORNEY/AGENT INFORMATION:
 27 NAME: Huse, Robert L.
 28 REGISTRATION NUMBER: 48,847
 29 REFERENCE/BOOKLET NUMBER: 184281
 30 TELECOMMUNICATION INFORMATION:
 31 TELEPHONE: (619) 678-5070
 32 TELEFAX: (619) 678-5099
 33 TELEX:
 34 INFORMATION FOR SEQ ID NO: 149:
 35 SEQUENCE CHARACTERISTICS:
 36 LENGTH: 18 amino acids
 37 TYPE: amino acid
 38 STRANDEDNESS: single
 39 MOLECULE TYPE: peptide
 40 DS-08-974-225-149

Query Match: 100.0% Score 19; Length 18
 Best Local Similarity: 100.0% Pred. No. of
 Matches: 4; Conservative 0; Mismatch 8; Gaps 0

VY 1 118G 4
 1111
 DB 11 118G 14

RESULT 12

FILING DATE: 28 JUN 1996
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: WILNER, Mario S.
 REGISTRATION NUMBER: 42,161
 REFERENCE/DECKET NUMBER: 1422-02641
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (703) 205, 8000
 TELEFAX: (703) 205-8050
 TELE: 248345
 INFORMATION FOR SEQ ID NO: 11:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 19 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 FRAGMENT TYPE: internal fragment
 US-08-672-571A-11

Query Match: 100.0% Score 192 E-16 Length 19
 Best Local Similarity: 100.0% Pred. No. 7 2
 Matches: 4: Conservative 0: Mismatches 0: gaps 0:

QY 1 FRG 4
 111
 18 FRG 11

RESULT 15
 US-09-025-151-24
 Sequence 24, Application US/09025151
 Patent No. 6,187,515
 GENERAL INFORMATION:
 APPLICANT: Legrain, Pierre
 APPLICANT: Fromont, Micheline
 APPLICANT: Ratin, Jean-Christophe
 TITLE OF INVENTION: FAST AND EXHAUSTIVE METHOD FOR SELECTING A PEPTIDE
 TITLE OF INVENTION: POLYPEPTIDE INTERACTING WITH A RAIL POLYPEPTIDE OF
 TITLE OF INVENTION: INTEREST: APPLICATION T 11: CONSTRUCTION OF BARS OF
 TITLE OF INVENTION: INTERACTORS POLYPEPTIDES
 FILE REFERENCE: 03495-0164
 CURRENT APPLICATION NUMBER: 09/092025, 151
 CURRENT FILING DATE: 1998-02-18
 NUMBER OF SEQ ID NOS: 25
 SOFTWARE: Patatid Ver. 2.5
 SEQ ID NO: 24
 LENGTH: 68
 TYPE: PRT
 ORGANISM: Saccharomyces cerevisiae
 US-09-025-151-24

Query Match: 100.0% Score 192 E-16 Length 19
 Best Local Similarity: 100.0% Pred. No. 2,800 1
 Matches: 4: Conservative 0: Mismatches 0: gaps 0:

QY 1 FRG 4
 111
 22 FRG 25

Search completed: September 13, 2002, 09:41:39
 Job time: 644 sec

•
•
•

bioCore version 4.5
Copyright (c) 1993 - 2000 bioCore Ltd.

HM protein - Protein search using SW model

Run on: September 11, 2002, 09:56:52, 11:11:26, 11:11:26, 11:11:26
(with local updates)

27,740 Million cell updates/sec

Title: ILE-LEU-ARG-GLY
Protein Source: 1
Sequence: 1 LEU 4

Scoring tables: BLOSUM62
Gapop: 10.0, Gapext: 0.5

Searches: 56,222 seqs, 172,934,929 residues

Total number of hits satisfying chosen parameters: 15,222

Minimum hit seq length: 0
Maximum hit seq length: 200,000,000

Post-processing: Minimum March: 08
Maximum March: 1008

Listing first 45 summaries

Database:

- 1: SP_ARCHAEB*
2: SP_BACTERIA*
3: SP_FUNGI*
4: SP_INVERTEBRATA*
5: SP_MAMMAL*
6: SP_PLANT*
7: SP_PROTOZ*
8: SP_ORNITHO*
9: SP_PLANT*
10: SP_PLANT*
11: SP_PROTOZ*
12: SP_VIRUS*
13: SP_VERTICILL*
14: SP_ZOOCLASSIFIED*
15: SP_ZOOCLASSIFIED*
16: SP_ZOOCLASSIFIED*
17: SP_ZOOCLASSIFIED*

Prod. No. is the number of results produced. It may be a value greater than or equal to the search value, if a result is found. It is derived by analysis of the total score for the hit.

SUMMARIES

Result No.	Score	Query Match	Match length	DB	ID	Accession
1	19	100.0	23	6	Q9TK14	Q9TK14 Bos taurus
2	19	100.0	28	15	Q71995	Q71995 human tubul
3	19	100.0	35	4	Q96E73	Q96E73 Homo sapien
4	19	100.0	36	15	Q76042	Q76042 human immun
5	19	100.0	47	14	P82839	P82839 Arabidopsis
6	19	100.0	49	6	Q98255	Q98255 Bos taurus
7	19	100.0	47	16	Q94Y14	Q94Y14 Arabidopsis
8	19	100.0	49	5	Q26787	Q26787 Trypsinogen
9	19	100.0	50	1	Q94677	Q94677 Salivary
10	19	100.0	52	5	Q26173	Q26173 Plasmodium
11	19	100.0	53	2	Q98058	Q98058 Streptococcus
12	19	100.0	53	16	Q98255	Q98255 Bos taurus
13	19	100.0	56	7	Q9M665	Q9M665 Alkaline phos
14	19	100.0	58	5	Q18191	Q18191 Caseinogen
15	19	100.0	58	5	Q26174	Q26174 Plasmodium
16	19	100.0	60	11	Q61424	Q61424 Mus musculus

17	19	100.0	61	1	Q98114	Q98114 Bos taurus
18	19	100.0	62	16	Q98255	Q98255 Bos taurus
19	19	100.0	62	16	Q98255	Q98255 Bos taurus
20	19	100.0	62	16	Q98255	Q98255 Bos taurus
21	19	100.0	62	16	Q98255	Q98255 Bos taurus
22	19	100.0	62	16	Q98255	Q98255 Bos taurus
23	19	100.0	62	16	Q98255	Q98255 Bos taurus
24	19	100.0	62	16	Q98255	Q98255 Bos taurus
25	19	100.0	62	16	Q98255	Q98255 Bos taurus
26	19	100.0	62	16	Q98255	Q98255 Bos taurus
27	19	100.0	62	16	Q98255	Q98255 Bos taurus
28	19	100.0	62	16	Q98255	Q98255 Bos taurus
29	19	100.0	62	16	Q98255	Q98255 Bos taurus
30	19	100.0	62	16	Q98255	Q98255 Bos taurus
31	19	100.0	62	16	Q98255	Q98255 Bos taurus
32	19	100.0	62	16	Q98255	Q98255 Bos taurus
33	19	100.0	62	16	Q98255	Q98255 Bos taurus
34	19	100.0	62	16	Q98255	Q98255 Bos taurus
35	19	100.0	62	16	Q98255	Q98255 Bos taurus
36	19	100.0	62	16	Q98255	Q98255 Bos taurus
37	19	100.0	62	16	Q98255	Q98255 Bos taurus
38	19	100.0	62	16	Q98255	Q98255 Bos taurus
39	19	100.0	62	16	Q98255	Q98255 Bos taurus
40	19	100.0	62	16	Q98255	Q98255 Bos taurus
41	19	100.0	62	16	Q98255	Q98255 Bos taurus
42	19	100.0	62	16	Q98255	Q98255 Bos taurus
43	19	100.0	62	16	Q98255	Q98255 Bos taurus
44	19	100.0	62	16	Q98255	Q98255 Bos taurus
45	19	100.0	62	16	Q98255	Q98255 Bos taurus

ALIGNMENTS

RESULT 1	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
1	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
2	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
3	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
4	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
5	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
6	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
7	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
8	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
9	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
10	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
11	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
12	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
13	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
14	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
15	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
16	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
17	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
18	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
19	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
20	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
21	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
22	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
23	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
24	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
25	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
26	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
27	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
28	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
29	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
30	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
31	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
32	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
33	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
34	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
35	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
36	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
37	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
38	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
39	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
40	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
41	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
42	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
43	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
44	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus
45	ILE-LEU-ARG-GLY	Q9TK14	Q9TK14 Bos taurus

01 01-DEP2001 (1TEMPLOC_19, last annotation)
DE HYPOPHYSICAL 7.3 KDA PROTEIN.
GN C26B2.5.
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematozoa; Chromadorea; Eudorhiza; Platyhelminthes;
OC Platyhelminthes; Polychaeta; Chromadorea.
OX NCBI TaxID=6239.
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-BRISTOL N2.
FX MEDLINE:93669613; PubMed:9851915;
RA None;
RI "Genome sequence of the nematode *C. elegans*: a platform for
R1 investigating biology. The *C. elegans* Sequencing Consortium."
R2 Science. 282:2012-2018 (1998).
RL [2]
RN SEQUENCE FROM N.A.
RC STRAIN-BRISTOL N2;
RA None;
RI "The sequence of *C. elegans* would be 98.2 %
R2 identical to the *Drosophila* genome."
R3 Science. 282:2012-2018 (1998).
RL [3]
RN SEQUENCE FROM N.A.
RC STRAIN-BRISTOL N2;
RA Waterston R.;
RI "Direct Submission."
R2 Submitted (Aug-2-201) to the EMBL/GenBank/Trinity databases.
RL EMBL: 041557; AAC24250.1;
RW Hypophyseal protein.
SW SQUIDBITE; FS AA: 6398 MW: 66496.45 kDa; 151 aa; 151

Only Math	100.0%	Score 100	100.0%
Fast Forward <td>100.0% <td>Score 100 <td>100.0%</td> </td></td>	100.0% <td>Score 100 <td>100.0%</td> </td>	Score 100 <td>100.0%</td>	100.0%
Matches	4	Conservative	100.0%
Q7	1.14%	4	
Ed	5.14%	8	

RESID	15
ID	Q26174
AC	Q26174:
DI	01-NOV-1995 (FEBBLR) 01, (Treated)
D1	01-NOV-1995 (FEBBLR) 01, Last sequence update
D1	01-JUN-2001 (FEBBLR) 19, Last annotation update
DE	GAM1 PROTEIN (FRAGMENT).
GN	GAM1.
OS	Fusobacterium vivax;
OC	Eubacteriales; Alphaproteobacteria; Acidimicrobiales; Bacteroidetes; Spirochaetia;
OX	NCHL_14816.1(85%)
RN	[1]
RP	SEQUENCE FROM N.A.
PX	MEDIAN OF 157 GENES FROM T845477;
KA	SHEWEN V.A., KHOUFI E.S., MATTHEVAIDARAKIS J., PETERLIN L., FRIMMELMAN S.,
RT	MENGES K.N., DAVID P.H.;
RI	"A new polymorphic marker for PCR typing of Leishmania vivax
PL	parasites.";
RL	MOL. BIOCHEM. PARASITOL. 71:145-148(1995)
DR	EMBL: X84673; CAA59105.1(-);
FT	NON_TTR 1
ET	NON_TTR 58
SQ	SEQUENCE 18 AA, GAT AGG AAGGAGGGTCAAGCCTGTGTTG

Identity Match	100.0%	Score 19	13.0%	Length 5M
Best Local Similarity	100.0%	Pred. No.	6	8
Methods	4	Conservative	0	Matches
07	1	File 4		
	111			

[illegible]

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Copyright (c) 1993 - 2000 by Kluwer Academic Publishers.

MM protein - protein search, using sw model

Run on:
September 13, 2002, 09:23:45 : ... : h... : ...
Savannah

(iii) M_i is identical to M_i for $i \in \{1, \dots, n\}$.

Title: $[[H^1, H^1]]$ -AK(2)-HYPERALGEBRAS

1. $\mathcal{H} = \{H_1, \dots, H_n\}$
 2. $\mathcal{H} = \{H_1, \dots, H_n\}$
 3. $\mathcal{H} = \{H_1, \dots, H_n\}$
 4. $\mathcal{H} = \{H_1, \dots, H_n\}$
 5. $\mathcal{H} = \{H_1, \dots, H_n\}$
 6. $\mathcal{H} = \{H_1, \dots, H_n\}$
 7. $\mathcal{H} = \{H_1, \dots, H_n\}$
 8. $\mathcal{H} = \{H_1, \dots, H_n\}$
 9. $\mathcal{H} = \{H_1, \dots, H_n\}$
 10. $\mathcal{H} = \{H_1, \dots, H_n\}$

Figure 1. The structure of the proposed model.

Summary

See Table 1 for details

100
 90
 80
 70
 60
 50
 40
 30
 20
 10
 0
 0 10 20 30 40 50 60 70 80 90 100
 Age (years)

Submitted: 10⁵224 September, 2017

Total number of hits satisfying chosen parameter: 104,223

Mini-journal

Maximum DB Seq Length: 260000000

POST-PROCESSING: MINIMUM MATCEN: 99

This inquiry first of summer 1905

Database : SwissProt_40:*

pred. No. is the number of results predicted to have a score greater than or equal to the score of the result being predicted, and is derived by analysis of the total score distribution.

SUMMARY

Result	Score	Query	Match	Length	DB	Description
No.						
1	19	100.0	34	1	EF1N_PROVU	P24779 proteins vitu
2	19	100.0	43	1	H0SL_ANEUS	P11444 ornithine S
3	19	100.0	5/2	1	YPYC_F04.1	P14454 ornithine S
4	19	100.0	6/4	1	CPHE_F04.2	P14454 ornithine S
5	19	100.0	7/5	1	YK12_HEMA	P24780 S-layer AIB
6	19	100.0	7/5	1	PX01_HUMAN	P24780 S-layer AIB
7	19	100.0	7/7	1	K0X1_YEAST	P24780 S-layer AIB
8	19	100.0	9/0	1	C021_PETHY	P46744 S-layer AIB
9	19	100.0	9/4	1	Y076_ABP01	P46744 S-layer AIB
10	19	100.0	9/9	1	Y112_STNAL	P24780 S-layer AIB
11	19	100.0	10/1	1	VF15_BPAPS	P24780 S-layer AIB
12	19	100.0	10/5	1	U013_AIRMA	P24780 S-layer AIB
13	19	100.0	16/7	1	VNS1_EYH	P24780 S-layer AIB
14	19	100.0	11/5	1	Y037_YEAST	P24780 S-layer AIB
15	19	100.0	11/7	1	BL24_MCT18	P24780 S-layer AIB
16	19	100.0	12/2	1	YH11_AZO18	P24780 S-layer AIB
17	19	100.0	12/5	1	MEKE_STRI1	P24780 S-layer AIB
18	19	100.0	12/9	1	NK1_P10	P24780 S-layer AIB
19	19	100.0	13/0	1	U133_HSV11	P24780 S-layer AIB
20	19	100.0	14/2	1	PE13_F04.0	P24780 S-layer AIB
21	19	100.0	14/4	1	BL13_AQUAE	P24780 S-layer AIB
22	19	100.0	14/5	1	ME27_YEAST	P24780 S-layer AIB
23	19	100.0	14/5	1	BL11_HAN50	P24780 S-layer AIB
24	19	100.0	14/5	1	BL18_STA7A	P24780 S-layer AIB
25	19	100.0	14/6	1	BL11_BO060	P24780 S-layer AIB
26	19	100.0	14/7	1	U14_RAT	P24780 S-layer AIB
27	19	100.0	14/7	1	BL13_STR09	P24780 S-layer AIB
28	19	100.0	14/7	1	YAH3_SHEP	P24780 S-layer AIB
29	19	100.0	14/8	1	ME01_ECO11	P24780 S-layer AIB
30	19	100.0	14/8	1	ME01_COE01	P24780 S-layer AIB
31	19	100.0	14/9	1	BL13_CHUPN	P24780 S-layer AIB
32	19	100.0	15/0	1	CN01_B0VIN	P24780 S-layer AIB
33	19	100.0	15/0	1	CN01_HERMA	P24780 S-layer AIB

44	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
45	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
46	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
47	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
48	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
49	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
50	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
51	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
52	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
53	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
54	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
55	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
56	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
57	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
58	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
59	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
60	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
61	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
62	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
63	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
64	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
65	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
66	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
67	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
68	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
69	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
70	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
71	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
72	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
73	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
74	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
75	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
76	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
77	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
78	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
79	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
80	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
81	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
82	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
83	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
84	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
85	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
86	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
87	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
88	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
89	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
90	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
91	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
92	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
93	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
94	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
95	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
96	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
97	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
98	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
99	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00
100	1.9	100.00	150	1	Y-71	Y-71	100.00	100.00

100

[illegible]

ANNALS

[illegible][illegible][illegible][illegible]

1. $\frac{1}{2}$ 2. $\frac{1}{3}$ 3. $\frac{1}{4}$ 4. $\frac{1}{5}$ 5. $\frac{1}{6}$ 6. $\frac{1}{7}$ 7. $\frac{1}{8}$ 8. $\frac{1}{9}$ 9. $\frac{1}{10}$ 10. $\frac{1}{11}$ 11. $\frac{1}{12}$ 12. $\frac{1}{13}$ 13. $\frac{1}{14}$ 14. $\frac{1}{15}$ 15. $\frac{1}{16}$ 16. $\frac{1}{17}$ 17. $\frac{1}{18}$ 18. $\frac{1}{19}$ 19. $\frac{1}{20}$ 20. $\frac{1}{21}$ 21. $\frac{1}{22}$ 22. $\frac{1}{23}$ 23. $\frac{1}{24}$ 24. $\frac{1}{25}$ 25. $\frac{1}{26}$ 26. $\frac{1}{27}$ 27. $\frac{1}{28}$ 28. $\frac{1}{29}$ 29. $\frac{1}{30}$ 30. $\frac{1}{31}$ 31. $\frac{1}{32}$ 32. $\frac{1}{33}$ 33. $\frac{1}{34}$ 34. $\frac{1}{35}$ 35. $\frac{1}{36}$ 36. $\frac{1}{37}$ 37. $\frac{1}{38}$ 38. $\frac{1}{39}$ 39. $\frac{1}{40}$ 40. $\frac{1}{41}$ 41. $\frac{1}{42}$ 42. $\frac{1}{43}$ 43. $\frac{1}{44}$ 44. $\frac{1}{45}$ 45. $\frac{1}{46}$ 46. $\frac{1}{47}$ 47. $\frac{1}{48}$ 48. $\frac{1}{49}$ 49. $\frac{1}{50}$ 50. $\frac{1}{51}$ 51. $\frac{1}{52}$ 52. $\frac{1}{53}$ 53. $\frac{1}{54}$ 54. $\frac{1}{55}$ 55. $\frac{1}{56}$ 56. $\frac{1}{57}$ 57. $\frac{1}{58}$ 58. $\frac{1}{59}$ 59. $\frac{1}{60}$ 60. $\frac{1}{61}$ 61. $\frac{1}{62}$ 62. $\frac{1}{63}$ 63. $\frac{1}{64}$ 64. $\frac{1}{65}$ 65. $\frac{1}{66}$ 66. $\frac{1}{67}$ 67. $\frac{1}{68}$ 68. $\frac{1}{69}$ 69. $\frac{1}{70}$ 70. $\frac{1}{71}$ 71. $\frac{1}{72}$ 72. $\frac{1}{73}$ 73. $\frac{1}{74}$ 74. $\frac{1}{75}$ 75. $\frac{1}{76}$ 76. $\frac{1}{77}$ 77. $\frac{1}{78}$ 78. $\frac{1}{79}$ 79. $\frac{1}{80}$ 80. $\frac{1}{81}$ 81. $\frac{1}{82}$ 82. $\frac{1}{83}$ 83. $\frac{1}{84}$ 84. $\frac{1}{85}$ 85. $\frac{1}{86}$ 86. $\frac{1}{87}$ 87. $\frac{1}{88}$ 88. $\frac{1}{89}$ 89. $\frac{1}{90}$ 90. $\frac{1}{91}$ 91. $\frac{1}{92}$ 92. $\frac{1}{93}$ 93. $\frac{1}{94}$ 94. $\frac{1}{95}$ 95. $\frac{1}{96}$ 96. $\frac{1}{97}$ 97. $\frac{1}{98}$ 98. $\frac{1}{99}$ 99. $\frac{1}{100}$ 100. $\frac{1}{101}$ 101. $\frac{1}{102}$ 102. $\frac{1}{103}$ 103. $\frac{1}{104}$ 104. $\frac{1}{105}$ 105. $\frac{1}{106}$ 106. $\frac{1}{107}$ 107. $\frac{1}{108}$ 108. $\frac{1}{109}$ 109. $\frac{1}{110}$ 110. $\frac{1}{111}$ 111. $\frac{1}{112}$ 112. $\frac{1}{113}$ 113. $\frac{1}{114}$ 114. $\frac{1}{115}$ 115. $\frac{1}{116}$ 116. $\frac{1}{117}$ 117. $\frac{1}{118}$ 118. $\frac{1}{119}$ 119. $\frac{1}{120}$ 120. $\frac{1}{121}$ 121. $\frac{1}{122}$ 122. $\frac{1}{123}$ 123. $\frac{1}{124}$ 124. $\frac{1}{125}$ 125. $\frac{1}{126}$ 126. $\frac{1}{127}$ 127. $\frac{1}{128}$ 128. $\frac{1}{129}$ 129. $\frac{1}{130}$ 130. $\frac{1}{131}$ 131. $\frac{1}{132}$ 132. $\frac{1}{133}$ 133. $\frac{1}{134}$ 134. $\frac{1}{135}$ 135. $\frac{1}{136}$ 136. $\frac{1}{137}$ 137. $\frac{1}{138}$ 138. $\frac{1}{139}$ 139. $\frac{1}{140}$ 140. $\frac{1}{141}$ 141. $\frac{1}{142}$ 142. $\frac{1}{143}$ 143. $\frac{1}{144}$ 144. $\frac{1}{145}$ 145. $\frac{1}{146}$ 146. $\frac{1}{147}$ 147. $\frac{1}{148}$ 148. $\frac{1}{149}$ 149. $\frac{1}{150}$ 150. $\frac{1}{151}$ 151. $\frac{1}{152}$ 152. $\frac{1}{153}$ 153. $\frac{1}{154}$ 154. $\frac{1}{155}$ 155. $\frac{1}{156}$ 156. $\frac{1}{157}$ 157. $\frac{1}{158}$ 158. $\frac{1}{159}$ 159. $\frac{1}{160}$ 160. $\frac{1}{161}$ 161. $\frac{1}{162}$ 162. $\frac{1}{163}$ 163. $\frac{1}{164}$ 164. $\frac{1}{165}$ 165. $\frac{1}{166}$ 166. $\frac{1}{167}$ 167. $\frac{1}{168}$ 168. $\frac{1}{169}$ 169. $\frac{1}{170}$ 170. $\frac{1}{171}$ 171. $\frac{1}{172}$ 172. $\frac{1}{173}$ 173. $\frac{1}{174}$ 174. $\frac{1}{175}$ 175. $\frac{1}{176}$ 176. $\frac{1}{177}$ 177. $\frac{1}{178}$ 178. $\frac{1}{179}$ 179. $\frac{1}{180}$ 180. $\frac{1}{181}$ 181. $\frac{1}{182}$ 182. $\frac{1}{183}$ 183. $\frac{1}{184}$ 184. $\frac{1}{185}$ 185. $\frac{1}{186}$ 186. $\frac{1}{187}$ 187. $\frac{1}{188}$ 188. $\frac{1}{189}$ 189. $\frac{1}{190}$ 190. $\frac{1}{191}$ 191. $\frac{1}{192}$ 192. $\frac{1}{193}$ 193. $\frac{1}{194}$ 194. $\frac{1}{195}$ 195. $\frac{1}{196}$ 196. $\frac{1}{197}$ 197. $\frac{1}{198}$ 198. $\frac{1}{199}$ 199. $\frac{1}{200}$ 200. $\frac{1}{201}$ 201. $\frac{1}{202}$ 202. $\frac{1}{203}$ 203. $\frac{1}{204}$ 204. $\frac{1}{205}$ 205. $\frac{1}{206}$ 206. $\frac{1}{207}$ 207. $\frac{1}{208}$ 208. $\frac{1}{209}$ 209. $\frac{1}{210}$ 210. $\frac{1}{211}$ 211. $\frac{1}{212}$ 212. $\frac{1}{213}$ 213. $\frac{1}{214}$ 214. $\frac{1}{215}$ 215. $\frac{1}{216}$ 216. $\frac{1}{217}$ 217. $\frac{1}{218}$ 218. $\frac{1}{219}$ 219. $\frac{1}{220}$ 220. $\frac{1}{221}$ 221. $\frac{1}{222}$ 222. $\frac{1}{223}$ 223. $\frac{1}{224}$ 224. $\frac{1}{225}$ 225. $\frac{1}{226}$ 226. $\frac{1}{227}$ 227. $\frac{1}{228}$ 228. $\frac{1}{229}$ 229. $\frac{1}{230}$ 230. $\frac{1}{231}$ 231. $\frac{1}{232}$ 232. $\frac{1}{233}$ 233. $\frac{1}{234}$ 234. $\frac{1}{235}$ 235. $\frac{1}{236}$ 236. $\frac{1}{237}$ 237. $\frac{1}{238}$ 238. $\frac{1}{239}$ 239. $\frac{1}{240}$ 240

Figure 1. Schematic representation of the experimental design. The subjects were divided into two groups: the control group (C) and the experimental group (E). The control group (C) was divided into two subgroups: the control group (C) and the control group (C). The experimental group (E) was divided into two subgroups: the experimental group (E) and the experimental group (E). The control group (C) was divided into two subgroups: the control group (C) and the control group (C). The experimental group (E) was divided into two subgroups: the experimental group (E) and the experimental group (E).

DECLARATION

[illegible][illegible]

	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	

1. Introduction

Abstract

— *1111111111*

[illegible]

1 NUCLEOTIDE SEQUENCE OF THE
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532
 533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548
 549
 550
 551
 552
 553
 554
 555
 556
 557
 558
 559
 560
 561
 562
 563
 564
 565
 566
 567
 568
 569
 570
 571
 572
 573
 574
 575
 576
 577
 578
 579
 580
 581
 582
 583
 584
 585
 586
 587
 588
 589
 590
 591
 592
 593
 594
 595
 596
 597
 598
 599
 600
 601
 602
 603
 604
 605
 606
 607
 608
 609
 610
 611
 612
 613
 614
 615
 616
 617
 618
 619
 620
 621
 622
 623
 624
 625
 626
 627
 628
 629
 630
 631
 632
 633
 634
 635
 636
 637
 638
 639
 640
 641
 642
 643
 644
 645
 646
 647
 648
 649
 650
 651
 652
 653
 654
 655
 656
 657
 658
 659
 660
 661
 662
 663
 664
 665
 666
 667
 668
 669
 670
 671
 672
 673
 674
 675
 676
 677
 678
 679
 680
 681
 682
 683
 684
 685
 686
 687
 688
 689
 690
 691
 692
 693
 694
 695
 696
 697
 698
 699
 700
 701
 702
 703
 704
 705
 706
 707
 708
 709
 710
 711
 712
 713
 714
 715
 716
 717
 718
 719
 720
 721
 722
 723
 724
 725
 726
 727
 728
 729
 730
 731
 732
 733
 734
 735
 736
 737
 738
 739
 740
 741
 742
 743
 744
 745
 746
 747
 748
 749
 750
 751
 752
 753
 754
 755
 756
 757
 758
 759
 760
 761
 762
 763
 764
 765
 766
 767
 768
 769
 770
 771
 772
 773
 774
 775
 776
 777
 778
 779
 780
 781
 782
 783
 784
 785
 786
 787
 788
 789
 790
 791
 792
 793
 794
 795
 796
 797
 798
 799
 800
 801
 802
 803
 804
 805
 806
 807
 808
 809
 810
 811
 812
 813
 814
 815
 816
 817
 818
 819
 820
 821
 822
 823
 824
 825
 826
 827
 828
 829
 830
 831
 832
 833
 834
 835
 836
 837
 838
 839
 840
 841
 842
 843
 844
 845
 846
 847
 848
 849
 850
 851
 852
 853
 854
 855
 856
 857
 858
 859
 860
 861
 862
 863
 864
 865
 866
 867
 868
 869
 870
 871
 872
 873
 874
 875
 876
 877
 878
 879
 880
 881
 882
 883
 884
 885
 886
 887
 888
 889
 890
 891
 892
 893
 894
 895
 896
 897
 898
 899
 900
 901
 902
 903
 904
 905
 906
 907
 908
 909
 910
 911
 912
 913
 914
 915
 916
 917
 918
 919
 920
 921
 922
 923
 924
 925
 926
 927
 928
 929
 930
 931
 932
 933
 934
 935
 936
 937
 938
 939
 940
 941
 942
 943
 944
 945
 946
 947
 948
 949
 950
 951
 952
 953
 954
 955
 956
 957
 958
 959
 960
 961
 962
 963
 964
 965
 966
 967
 968
 969
 970
 971
 972
 973
 974
 975
 976
 977
 978
 979
 980
 981
 982
 983
 984
 985
 986
 987
 988
 989
 990
 991
 992
 993
 994
 995
 996
 997
 998
 999
 1000

FA Robinson (1994) and others. *Journal of Clinical Investigation*,
 F1 Submitted (1994) and others. *Journal of Clinical Investigation*,
 F2 161.
 F3 CHARACTERIZATION, AND GENOME
 F4 MEDLINE-05362656; PubMed-763817.
 F5 The *Yersinia enterocolitica* genome has been sequenced by H.
 F6 Reschke et al. (1994) and the genes required for cytochrome oxidase
 F7 J. Bacteriol. 177:421-426 (1995).
 F8 -1. PUBMED: 763817 and others. *Journal of Clinical Investigation*,
 F9 BIOGENESIS OF CYTOCHROMES (CYTOCHROME
 F10 -1. SWISS-PROT: P12222; Trp, 1994, 1995).
 F11 This SWISS-PROT entry is copyright. It is provided through a collaboration
 F12 between the Swiss Institute of Bioinformatics and the EMBL Outstation
 F13 the European Bioinformatics Institute. There are no restrictions on its
 F14 use by non-profit institutions as long as the restrictions are in no way
 F15 modified and this statement is not removed, added to, and its commercial
 F16 entities require a license to use it (see <http://www.ebi.ac.uk/seqdb/doc/seqdb.html>).
 F17 or send an email to license@sb-sib.ch).
 F18
 F19 EMBL: E000008; AAI6190.1;
 F20 EMBL: A0000109; AAC75258.1;
 F21 EMBL: A0055452; AAG57353.1;
 F22 EMBL: A0055460; BAB5510.1;
 F23 ECGene: E312169; ccm.
 F24 Cytocrome c-type biogenesis; Transport; Membrane
 F25 Inner membrane; Complete proteome.
 F26 TRANSMEM 18 37
 F27 POLYNTAL
 F28 SEQUENCE 65AA: 7745 MW: BECID3AIEEDAO19 2064;

Query Match	100.0%	Score 19	181	Length 69
Best Local Similarity	100.0%	Prod. No.	1	Level 0
Matches	4	Conservative	0	Mismatched
			0	Models
			0	Clones
			0	

QY	1	11.8G	4
DO	46	11.8G	49

RESULT	5
YE67_THEME	
ID	YE67_THEME
AC	Q9X1Q3
D1	30-MAY-2000 (Ref. 39, created)
D1	30-MAY-2000 (Ref. 39, last sequence update)
D1	16-OCT-2001 (Ref. 40, last annotation update)
DE	Hypothetical protein TM1567

08 Thermotoga maritima
09 Bacteroides Thermotogales, Thermotoga
10 NCBI_ID=12336;
11
12
13 SEQUENCE FROM N.A.
14 STAIN-MSB / DSM 3109;
15 MEDLINE=92287316; PubMed=10360571;
16 Nelson K.B., Clayton R.A., Gill S.R., Cox M.,
17 Hatt P.H., Hickey E.R., Peterson J.C.,
18 McDonald I., Moravsek P., Major J.A.,
19 Stewart A.M., Cotton M.P., Major J.A.,
20 Heidelberg J., Sutton G.G., Fleischmann R.D.,
21 Salzberg S.L., Smith H.O., Venter J.C., Fraser M.
22 "Evidence for lateral gene transfer between *Archaea* and *Bacteria* from
23 genome sequences of *Thermotoga maritima*."
24 Nature 399:423-429(1999)
25
26 -1- SIMILARITY: BELONGS TO THE OPF0109 FAMILY.
27
28 -1- SIMILARITY: CONTAINS 1 KH DOMAIN.

This SWISS-PROT entry is copyright. It is protected through a collaboration between the Swiss Institute of Bioinformatics and the EMBL consortium. CC the European Bioinformatics Institute. Part of the publication of the CC use by non-profit institutions as long as its content is in no way CC modified and this statement is not removed, and for commercial

For conditions requiring a pre-arrangement (see <http://www.icsi.org>), or send an email to info@icsi.org.

[illegible][illegible]

U_1	1	1,1,1,1	4
	1	1	1
U_2	8	1,1,1,1	1

	RESULT	6
FOXG_HUMAN		
15-FOXG_HUMAN	SEQUENCE	INT. 73 bp
AC Q15357		
DT 15-JUL-1999	(Ref.: 48) (revised)	
DT 15-JUL-1999	(Ref.: 48) Last sequence update	
DT 16-OCT-2001	(Ref.: 40) Last annotation update	
DE Small nuclear ribonucleoprotein G (SNRNG) [cDNA] (50-72) (50-72)		
DE (50-72)		

03: Homo sapiens (human)
04: Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
05: Mammalia; Eulipotyphla; Soricomorpha; 3rd order, 3rd
0X: NCBI_taxID: 9606;
[1] CN

RI SPOONING FROM N/A
RX MEDLINE#95262647; PubMed 7744044
KA Hermann H., Fauriol G., Beked V.A., Kothakota S., Luchman R.
"ASPRN" Smearing Glare To "Golfing" Glare: A Study Involving In Situ Protein Profiles In "Golfing" Glare.
KL EMBO J. 14:2076-2086(1999).

MR. STEPHEN FLECH, M.D.,
TISDIE-Placental
St. Paul, R.
Submitted (May 2000) to the Endocrine/Obstetrics
Committee of the American Society of Human
Genetics. This report is for informational
purposes only.

[illegible][illegible]

[illegible]

Figure 1. Schematic representation of the experimental design. The subjects were divided into two groups: the control group (CG) and the experimental group (EG). The CG was divided into two subgroups: the control group (CG) and the control group (CG). The EG was divided into two subgroups: the experimental group (EG) and the experimental group (EG). The CG was divided into two subgroups: the control group (CG) and the control group (CG). The EG was divided into two subgroups: the experimental group (EG) and the experimental group (EG).

100

EMBL: Z4288; CAA84156.1
 LOR EMBL: Z49442; CAA84157.1
 LOR PIR: S47124; S47124
 LOR SDB: S000603; Y1067W
 KM Hybrid local protein: Transmembrane
 E1 TRANSMEM 40 60 POTENTIAL
 E1 TRANSMEM 72 92 POTENTIAL
 SV SEQUENCE 119 AA; 1271a MW: 45477.00; pI: 5.04

Query Match: 100.0%; Score 19; 48; 1; 100.0%
 Best Local Similarity: 100.0%; Prod. No. 1; 100.0%
 Matches: 4; Conservative 0; Mismatches 0; Gaps 0

QY 1 IIRG 4
 11
 10 59 IIRG 62

RESULT 15
 RI24_MBL1H STANDARD ERL 117 AA
 AC 926122;
 DI 15-JUL-1998 (Rel. 46, Created)
 DI 15-JUL-1998 (Rel. 46, Last sequence update)
 DI 15-JUL-2001 (Rel. 46, Last annotation update)
 DE 508 ribosomal protein L24P.
 SN R0124P OR M1H14.
 OS Methanobacterium (Methanobacteriales,
 AC Archaea); Euryarchaeota; Methanobacteriales; Methanobacteriales;
 CC Methanobacteriales;
 CC NCBI_14811P-145262;
 GN 111
 RP SEQUENCE FROM N. A.
 RI STRAIN DELTA H;
 RX MEDLINE:98037514; PubMed 9471464;
 RA Smith L.R., Doncelle Stamm L.A., Delonguey C., Le B.M., Dubois J.,
 RA Alidre D., Roshizadeh R., Blakey D., Stoeckli R.,
 RA Harrison D., Hord D., Keadle P., Lamm W., Roth G., Gaudin D.,
 RA Spadaro R., Vitaro R., Wang Y., Wierzbowski J., Gibson R.,
 RA Jiwani N., Caruso A., Bush D., Sifer H., Jorgensen J., Jorgensen S.,
 RA McDougall S., Shiner G., Gayle A., Piotrowski S., Church G.M.,
 RA Daniels C.J., Mao J.-L., Rice P., Neill J., Jorgensen J.N.
 RI "Complete genome sequence of Methanobacterium thermoautotrophicum
 RI delta H: functional analysis and comparative genomics."
 RI J. Bacteriol. 179:7135-7155(1997).
 CC -1- SIMILARITY: BELONGS TO THE L24P FAMILY OF RIBOSOMAL PROTEINS.
 CC
 CC This SWISS-PROT entry is copyright. It is put up through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL database.
 CC The European Bioinformatics Institute, from 1990, restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed, replaced by and for commercial
 CC or send an email to license (sb@ebi.ac.uk).
 CC
 CC EMBL: A000755; A004515.1;
 CC InterPro: IPR004256; Ribosomal_L24.
 CC InterPro: IPR004020; Ribosomal_L24_NuS.
 CC Pfam: PF00467; Ribosomal_L24; 1.
 CC Protein: P001677; Ribosomal_L24; 1.
 CC Protein: P01108; Ribosomal_L24; 1; FALSE NEG.
 CC Ribosomal protein: Complete Proteome.
 CC SEQUENCE 117 AA; 13860 MW; 45477.00; pI: 5.04;

Query Match: 100.0%; Score 19; 48; 1; 100.0%
 Best Local Similarity: 100.0%; Prod. No. 1; 100.0%
 Matches: 4; Conservative 0; Mismatches 0; Gaps 0
 QY 1 IIRG 4
 111

11 59 IIRG 62
 Query completed: 09/13/2002 10:04:00
 134110001 box green

GenCore version 4.5
Copyright (c) 1993 - 2000 CMP Inc. Ltd.

OR Protein - Protein search, using 5% model

Run on: September 13, 2002, 09:24:10 - Search time: 15.13 Seconds

(Exit out of alignment)
25317 hit from coll updates/sec

Title: lle-leu-arg-gly
Perfect score: 19
Sequence: 1 ILRG 4

Scoring table:
BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 28319 seqs, 969924 residues

Total number of hits satisfying chosen parameters: 38118

Minimum DB seq length: 6
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: PIR71**
1: pir1**
2: pir2**
3: pir3**
4: pir4**

Prod N is the number of results greater than a score greater than or equal to the score of the result being printed, and is derived by analysis of the total results distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	19	100.0	34	A4098	leader peptide, Pla
2	19	100.0	39	G85837	hypothetical prote
3	19	100.0	43	S29763	aminopeptidase N -
4	19	100.0	43	A23041	actinital protein
5	19	100.0	50	2131019	hypothetical prote
6	19	100.0	51	S55419	GM1 protein, Pla
7	19	100.0	52	T08487	hypothetical prote
8	19	100.0	52	AE0410	hypothetical prote
9	19	100.0	53	B83853	hypothetical prote
10	19	100.0	57	S55452	GM1 protein, Pla
11	19	100.0	58	T44120	hypothetical prote
12	19	100.0	61	F81510	hypothetical prote
13	19	100.0	62	F92321	hypothetical prote
14	19	100.0	68	S55454	GM1 protein, Pla
15	19	100.0	68	S55455	GM1 protein, Pla
16	19	100.0	69	N61486	home exporter prot
17	19	100.0	69	G01014	home exporter prot
18	19	100.0	69	A85859	home exporter prot
19	19	100.0	70	AF0960	home exporter prot
20	19	100.0	70	A10787	home exporter prot
21	19	100.0	75	B72236	secreted hypokati
22	19	100.0	75	B97542	hypothetical prote
23	19	100.0	75	A92701	hypothetical prote
24	19	100.0	76	S7994	Sm 12, Pla
25	19	100.0	77	S15293	interactin alpha V-1
26	19	100.0	77	S48322	SH2 protein - yoa
27	19	100.0	77	AB0348	hypothetical prote
28	19	100.0	77	A12348	hypothetical prote
29	19	100.0	79	S55156	GM1 protein, Pla

30	19	100.0	80	A10787	interactin alpha V-1
31	19	100.0	83	A02416	hypothetical prote
32	19	100.0	85	J01140	hypothetical prote
33	19	100.0	87	J04128	hypothetical prote
34	19	100.0	89	A02240	hypothetical prote
35	19	100.0	92	S55411	hypothetical prote
36	19	100.0	96	S09452	hypothetical prote
37	19	100.0	96	T41164	hypothetical prote
38	19	100.0	97	H76439	hypothetical prote
39	19	100.0	97	S79429	hypothetical prote
40	19	100.0	97	S08155	hypothetical prote
41	19	100.0	99	A12927	hypothetical prote
42	19	100.0	99	S65061	hypothetical prote
43	19	100.0	104	E70541	hypothetical prote
44	19	100.0	105	S09766	hypothetical prote
45	19	100.0	105	T15114	hypothetical prote

SUMMARIES

RESULT 1
A4098
Leader peptide that - Proteus vulgaris
C:Species: Proteus vulgaris
C:Date: 10 Jun 1991 #Sequence: Revision 18 Nov 1991 rev. char. 24 Sep 1991
C:Accession: A4098
E:Kamath, A.V.; Vassilsky, V.
J. Biol. Chem. 267, 1997-1995, 1992
A:Title: Characterization of the triphosphatase activity of the protein A4098
A:Reference number: A4098
A:Accession: A4098
A>Status: preliminary; not compared with other sequences
A:Molecule type: nucleic acid
A:Accession: 1 24 5KMB
A:Cross reference: 28319 seqs, 969924 residues
A:Cross reference: 1100 hit from coll updates/sec
C:Importantly: nucleic acid peptides

Query Match: 100.0%, Score: 19, Length: 34
Best Local Similarity: 100.0%, Prod. No. 1, 19 seqs
Matches: 43 Conservatively 0 Mismatches: 0 Gaps: 0

DB: 1 ILRG 4
1111
10 ILRG 13

RESULT 2
G85837
hypothetical protein Z427, imported - Escherichia coli (strain 5592) substrate B
C:Species: Escherichia coli
C:Date: 14 Feb 2001 #Sequence: Revision 16 Nov 1991 rev. char. 24 Sep 1991
C:Accession: G85837
E:Perkins, N.T.; Plunkett, L.L.; 137000000, Y. 1991
A:Title: The Escherichia coli protein Z427, a member of the ABC transporter family, is a substrate for the ABC transporter
A:Reference number: G85837
A:Accession: G85837
A>Status: preliminary
A:Molecule type: DNA
A:Accession: 1 29 5KMB
A:Cross reference: 28319 seqs, 969924 residues
A:Cross reference: 1100 hit from coll updates/sec
A:Experimental source: strain 5592, substrate B
C:Genomes: 2
C:Date: 2001

Query Match: 100.0%, Score: 19, Length: 39
Best Local Similarity: 100.0%, Prod. No. 1, 19 seqs
Matches: 43 Conservatively 0 Mismatches: 0 Gaps: 0

10. 11. 2001

[illegible][illegible]

1. *Chlorophyll a* (Chl *a*) is the primary photosynthetic pigment in most plants and algae. It is a green pigment that absorbs light energy in the blue and red regions of the visible spectrum.

2. *Chlorophyll b* (Chl *b*) is an accessory pigment that absorbs light energy in the blue and orange-red regions of the visible spectrum. It transfers energy to Chl *a* for photosynthesis.

3. *Carotenoids* are a group of pigments that absorb light energy in the blue and green regions of the visible spectrum. They include carotenes and xanthophylls. Carotenoids transfer energy to Chl *a* and also protect the photosynthetic apparatus from damage by excess light.

4. *Xanthophylls* are a subgroup of carotenoids that absorb light energy in the blue and green regions of the visible spectrum. They play a role in photoprotection and energy transfer.

5. *Phycobilins* are water-soluble pigments found in cyanobacteria and red algae. They absorb light energy in the blue and green regions of the visible spectrum and transfer energy to Chl *a*.

6. *Anthocyanins* are water-soluble pigments that absorb light energy in the blue and green regions of the visible spectrum. They are responsible for the red, purple, and blue colors in many plants.

7. *Flavonoids* are a large group of pigments that absorb light energy in the blue and green regions of the visible spectrum. They include flavones, flavonols, and flavanols. Flavonoids are involved in various plant processes, including UV protection and signaling.

8. *Anthoxanthins* are water-soluble pigments that absorb light energy in the blue and green regions of the visible spectrum. They are responsible for the yellow and white colors in many plants.

9. *Anthocyanins* (repeated) are water-soluble pigments that absorb light energy in the blue and green regions of the visible spectrum. They are responsible for the red, purple, and blue colors in many plants.

10. *Anthocyanins* (repeated) are water-soluble pigments that absorb light energy in the blue and green regions of the visible spectrum. They are responsible for the red, purple, and blue colors in many plants.

[illegible][illegible]

Accepted for publication 12 November 2003
 Published online 12 December 2003

[illegible]

Model	Model description	Model parameters	Model results
Model 1	Model 1: A simple linear model	$y = a + bx$	$a = 1.2, b = 0.5$
Model 2	Model 2: A quadratic model	$y = a + bx + cx^2$	$a = 1.2, b = 0.5, c = 0.1$
Model 3	Model 3: A cubic model	$y = a + bx + cx^2 + dx^3$	$a = 1.2, b = 0.5, c = 0.1, d = 0.05$
Model 4	Model 4: A quartic model	$y = a + bx + cx^2 + dx^3 + ex^4$	$a = 1.2, b = 0.5, c = 0.1, d = 0.05, e = 0.01$
Model 5	Model 5: A quintic model	$y = a + bx + cx^2 + dx^3 + ex^4 + fx^5$	$a = 1.2, b = 0.5, c = 0.1, d = 0.05, e = 0.01, f = 0.005$
Model 6	Model 6: A sextic model	$y = a + bx + cx^2 + dx^3 + ex^4 + fx^5 + gx^6$	$a = 1.2, b = 0.5, c = 0.1, d = 0.05, e = 0.01, f = 0.005, g = 0.001$
Model 7	Model 7: A septic model	$y = a + bx + cx^2 + dx^3 + ex^4 + fx^5 + gx^6 + hx^7$	$a = 1.2, b = 0.5, c = 0.1, d = 0.05, e = 0.01, f = 0.005, g = 0.001, h = 0.0005$
Model 8	Model 8: An octic model	$y = a + bx + cx^2 + dx^3 + ex^4 + fx^5 + gx^6 + hx^7 + ix^8$	$a = 1.2, b = 0.5, c = 0.1, d = 0.05, e = 0.01, f = 0.005, g = 0.001, h = 0.0005, i = 0.0001$
Model 9	Model 9: A nonic model	$y = a + bx + cx^2 + dx^3 + ex^4 + fx^5 + gx^6 + hx^7 + ix^8 + jx^9$	$a = 1.2, b = 0.5, c = 0.1, d = 0.05, e = 0.01, f = 0.005, g = 0.001, h = 0.0005, i = 0.0001, j = 0.00005$
Model 10	Model 10: A decic model	$y = a + bx + cx^2 + dx^3 + ex^4 + fx^5 + gx^6 + hx^7 + ix^8 + jx^9 + kx^{10}$	$a = 1.2, b = 0.5, c = 0.1, d = 0.05, e = 0.01, f = 0.005, g = 0.001, h = 0.0005, i = 0.0001, j = 0.00005, k = 0.00001$

[illegible][illegible][illegible]

For the first time, we have shown that the β -phase of poly(2-vinylpyridine) is stable in the presence of a small amount of water. The β -phase is stable in the presence of water, even when the water content is as low as 0.1 wt.-%. This is the first time that the β -phase has been shown to be stable in the presence of water. The β -phase is stable in the presence of water, even when the water content is as low as 0.1 wt.-%. This is the first time that the β -phase has been shown to be stable in the presence of water.

[illegible]

Acknowledgments—The authors thank Dr. J. M. B. de Almeida for his critical reading of the manuscript.

$$\hat{A}_1 = \hat{M}_1 + \hat{A}_1^* \hat{A}_1, \quad \hat{A}_1^* = \hat{M}_1^* \hat{A}_1^* \hat{M}_1, \quad \hat{A}_1^* \hat{A}_1 = \hat{A}_1 \hat{A}_1^* = \hat{A}_1^2$$

2000	2
2001	3
2002	4
2003	5
2004	6
2005	7
2006	8
2007	9
2008	10
2009	11
2010	12
2011	13
2012	14
2013	15
2014	16
2015	17
2016	18
2017	19
2018	20
2019	21
2020	22
2021	23
2022	24
2023	25
2024	26
2025	27
2026	28
2027	29
2028	30
2029	31
2030	32
2031	33
2032	34
2033	35
2034	36
2035	37
2036	38
2037	39
2038	40
2039	41
2040	42
2041	43
2042	44
2043	45
2044	46
2045	47
2046	48
2047	49
2048	50
2049	51
2050	52
2051	53
2052	54
2053	55
2054	56
2055	57
2056	58
2057	59
2058	60
2059	61
2060	62
2061	63
2062	64
2063	65
2064	66
2065	67
2066	68
2067	69
2068	70
2069	71
2070	72
2071	73
2072	74
2073	75
2074	76
2075	77
2076	78
2077	79
2078	80
2079	81
2080	82
2081	83
2082	84
2083	85
2084	86
2085	87
2086	88
2087	89
2088	90
2089	91
2090	92
2091	93
2092	94
2093	95
2094	96
2095	97
2096	98
2097	99
2098	100
2099	101
2100	102
2101	103
2102	104
2103	105
2104	106
2105	107
2106	108
2107	109
2108	110
2109	111
2110	112
2111	113
2112	114
2113	115
2114	116
2115	117
2116	118
2117	119
2118	120
2119	121
2120	122
2121	123
2122	124
2123	125
2124	126
2125	127
2126	128
2127	129
2128	130
2129	131
2130	132
2131	133
2132	134
2133	135
2134	136
2135	137
2136	138
2137	139
2138	140
2139	141
2140	142
2141	143
2142	144
2143	145
2144	146
2145	147
2146	148
2147	149
2148	150
2149	151
2150	152
2151	153
2152	154
2153	155
2154	156
2155	157
2156	158
2157	159
2158	160
2159	161
2160	162
2161</	

[illegible]

1. 1990年12月25日，在俄罗斯莫斯科市克里姆林宫，俄罗斯总统叶利钦在克里姆林宫正式签署《俄罗斯联邦宪法》，宣布俄罗斯联邦为总统制国家。

C:Date: 02 Mar 2001 #sequence=protein 02 Mar 2001 #length=402 #size=2001
 A:Accession: AF0410
 R:Parkhill, J., Wen, B.W., Thomson, N.R., Tlusty, D.W., Holtz, M., De Proulx, M.B.,
 del-Torreal, A.M., Chilinsworth, T., Couto, A., Jones, R.M., Davis, P., Leonard, C.J.,
 L., M., Rubefeld, R., Simmons, H., Skellern, A., Stevens, K., Whithead, S., Parkhill,
 Nature 413, 521-527, 2001
 A>Title: Genome Sequence of *Yersinia pestis*, the causative agent of plague.
 A:Reference: AF0401; MIMD:2147641; EMBL:36856
 A:Accession: AF0410
 A>Status: Preliminary
 A:Molecule type: DNA
 A:Residues: 1-52 - KUS
 A:Cross-references: GB:AF159084; P:U015CA9265; U:U015CA9265; S:781 [Eukaryote]
 A:Genetic:
 A:Genot: Yp03479

Only March	100.00	Score 19	March 12
Post Local Similarity	100.00	Prod No	
Murphy's	1	Connecticut	March 12
QY	1	Elko	4
	1	1	
	1	1	
Ob	9	Elko	12

RESULT 9
E80854
 Hypothetical protein BH1626 [Imported] - Bacillus haloburans (strain 6145)
 C:Species: *Bacillus haloburans*
 C:Date: 01-Jan-2000 #sequence_revision 01-Jan-2001 #text_updates 15-Jun-2001
 C:Accession: AB49853
 R:Kishimoto, H., Nakase, K., Takahashi, Y., Kano, T., Kato, H., Matsuo, M., Fujita, T., Hara, K.
 Nucleic Acids Res. 28: 4317-4331, 2000
 A:Title: Complete genome sequence of the alkali-tolerant bacterium *Bacillus haloburans* and
 A:Reference number: AB4950; NCBI:25512582; JM 01-4172
 A:Accession: AB49852
 A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1753 (STD)
 A:Cross-references: CRI:AB091512; CRI:EA000001; NCBI:25512582; EMBL:AB091512; JGI:25512582
 A:Experimental source: strain 6145
 C:Genetics:
 C:Gene: BH1626

Query Match	100.0%	Score	19	Length	53
Best Local Similarity	100.0%	Freq. Ratio	1		
Matches	4	Conservative	0	Mismatches	0
				Indels	0
QY	1	LEQ	4		
DB	20	LEQ	24		

RESULT: 10
 S55452
 GAML Protein - Plasmodium vivax (isolates K16-45) (human)
 CSpecies: Plasmodium vivax
 CDate: 06-Sep-1996 #sequence_location 13 Mar 1996 #next_release 17 Mar 1996
 CAccession: S55452
 RStewin, V.A., Khorram, B., Watt, V., Lohr, J., Peto, R., & Peto, C. (1996) Mol. Biochem. Parasitol. 71, 141-148, 1996
 ATitle: A low polymorphic marker for P. vivax in Southeast Asia
 AReference number: S54419; M011095456790
 AAccession: S55452
 AStatus: Preliminary
 AMethod: PCR, DNA
 AAccession: 1-47 <NC>
 ACross-References: EMBL:X84674

100.08; SECT 19; 100.08; 100.08; 100.08

Post local similarity	1.000	0.976	0.980
Matchos	41	conserved	150
		of Matchos	150
Cys	1	His	4
	III		
Ile	49	Ile	45

[illegible]

Country	Material	Year	Number of Inhabitants	Number of Inhabitants in 1990	Number of Inhabitants in 2000
East Africa	1	1990	1	1	1
East Africa	2	1990	2	2	2
East Africa	3	1990	3	3	3
East Africa	4	1990	4	4	4
East Africa	5	1990	5	5	5
East Africa	6	1990	6	6	6
East Africa	7	1990	7	7	7
East Africa	8	1990	8	8	8
East Africa	9	1990	9	9	9
East Africa	10	1990	10	10	10
East Africa	11	1990	11	11	11
East Africa	12	1990	12	12	12
East Africa	13	1990	13	13	13
East Africa	14	1990	14	14	14
East Africa	15	1990	15	15	15
East Africa	16	1990	16	16	16
East Africa	17	1990	17	17	17
East Africa	18	1990	18	18	18
East Africa	19	1990	19	19	19
East Africa	20	1990	20	20	20
East Africa	21	1990	21	21	21
East Africa	22	1990	22	22	22
East Africa	23	1990	23	23	23
East Africa	24	1990	24	24	24
East Africa	25	1990	25	25	25
East Africa	26	1990	26	26	26
East Africa	27	1990	27	27	27
East Africa	28	1990	28	28	28
East Africa	29	1990	29	29	29
East Africa	30	1990	30	30	30
East Africa	31	1990	31	31	31
East Africa	32	1990	32	32	32
East Africa	33	1990	33	33	33
East Africa	34	1990	34	34	34
East Africa	35	1990	35	35	35
East Africa	36	1990	36	36	36
East Africa	37	1990	37	37	37
East Africa	38	1990	38	38	38
East Africa	39	1990	39	39	39
East Africa	40	1990	40	40	40
East Africa	41	1990	41	41	41
East Africa	42	1990	42	42	42
East Africa	43	1990	43	43	43
East Africa	44	1990	44	44	44
East Africa	45	1990	45	45	45
East Africa	46	1990	46	46	46
East Africa	47	1990	47	47	47
East Africa	48	1990	48	48	48
East Africa	49	1990	49	49	49
East Africa	50	1990	50	50	50
East Africa	51	1990	51	51	51
East Africa	52	1990	52	52	52
East Africa	53	1990	53	53	53
East Africa	54	1990	54	54	54
East Africa	55	1990	55	55	55
East Africa	56	1990	56	56	56
East Africa	57	1990	57	57	57
East Africa	58	1990	58	58	58
East Africa	59	1990	59	59	59
East Africa	60	1990	60	60	60
East Africa	61	1990	61	61	61
East Africa	62	1990	62	62	62
East Africa	63	1990	63	63	63
East Africa	64	1990	64	64	64
East Africa	65	1990	65	65	65
East Africa	66	1990	66	66	66
East Africa	67	1990	67	67	67
East Africa	68	1990	68	68	68
East Africa	69	1990	69	69	69
East Africa	70	1990	70	70	70
East Africa	71	1990	71	71	

[illegible]

Country	Material	Year	Number of cases	Number of deaths	Number of survivors
United States	Asbestos	1970-1979	1,000	100	900
United States	Asbestos	1980-1989	1,000	100	900
United States	Asbestos	1990-1999	1,000	100	900
United States	Asbestos	2000-2009	1,000	100	900
United States	Asbestos	2010-2019	1,000	100	900
United States	Asbestos	2020-2029	1,000	100	900
United States	Asbestos	2030-2039	1,000	100	900
United States	Asbestos	2040-2049	1,000	100	900
United States	Asbestos	2050-2059	1,000	100	900
United States	Asbestos	2060-2069	1,000	100	900
United States	Asbestos	2070-2079	1,000	100	900
United States	Asbestos	2080-2089	1,000	100	900
United States	Asbestos	2090-2099	1,000	100	900
United States	Asbestos	2100-2109	1,000	100	900
United States	Asbestos	2110-2119	1,000	100	900
United States	Asbestos	2120-2129	1,000	100	900
United States	Asbestos	2130-2139	1,000	100	900
United States	Asbestos	2140-2149	1,000	100	900
United States	Asbestos	2150-2159	1,000	100	900
United States	Asbestos	2160-2169	1,000	100	900
United States	Asbestos	2170-2179	1,000	100	900
United States	Asbestos	2180-2189	1,000	100	900
United States	Asbestos	2190-2199	1,000	100	900
United States	Asbestos	2200-2209	1,000	100	900
United States	Asbestos	2210-2219	1,000	100	900
United States	Asbestos	2220-2229	1,000	100	900
United States	Asbestos	2230-2239	1,000	100	900
United States	Asbestos	2240-2249	1,000	100	900
United States	Asbestos	2250-2259	1,000	100	900
United States	Asbestos	2260-2269	1,000	100	900
United States	Asbestos	2270-2279	1,000	100	900
United States	Asbestos	2280-2289	1,000	100	900
United States	Asbestos	2290-2299	1,000	100	900
United States	Asbestos	2300-2309	1,000	100	900
United States	Asbestos	2310-2319	1,000	100	900
United States	Asbestos	2320-2329	1,000	100	900
United States	Asbestos	2330-2339	1,000	100	900
United States	Asbestos	2340-2349	1,000	100	900
United States	Asbestos	2350-2359	1,000	100	900
United States	Asbestos	2360-2369	1,000	100	900
United States	Asbestos	2370-2379	1,000	100	900
United States	Asbestos	2380-2389	1,000	100	900
United States	Asbestos	2390-2399	1,000	100	900
United States	Asbestos	2400-2409	1,000	100	900
United States	Asbestos	2410-2419	1,000	100	900
United States	Asbestos	2420-2429	1,000	100	900
United States	Asbestos	2430-2439	1,000	100	900
United States	Asbestos	2440-2449	1,000	100	900
United States	Asbestos	2450-2459	1,000	100	900
United States	Asbestos	2460-2469	1,000	100	900
United States	Asbestos	2470-2479	1,000	100	900
United States	Asbestos	2480-2489	1,000	100	900
United States	Asbestos	2490-2499	1,000	100	900
United States	Asbestos	2500-2509	1,000	100	900
United States	Asbestos	2510-2519	1,000	100	900
United States	Asbestos	2520-2529	1,000	100	900
United States	Asbestos	2530-2539	1,000	100	900
United States	Asbestos	2540-2549	1,000	100	900
United States	Asbestos	2550-2559	1,000	100	900
United States	Asbestos	2560-2569	1,000	100	900

1. The first step in the synthesis of the peptide is the
 2. synthesis of the N-terminus. This is done by reacting
 3. the amino acid with a protecting group. The protecting
 4. group is then removed and the amino acid is coupled
 5. to the growing chain. This process is repeated until
 6. the full peptide is synthesized. The peptide is then
 7. purified and characterized. The peptide is then
 8. used in various experiments. The peptide is then
 9. used in various experiments. The peptide is then
 10. used in various experiments.

1. The first step in the synthesis of the peptide is the
 2. synthesis of the N-terminus. This is done by reacting
 3. the amino acid with a protecting group. The protecting
 4. group is then removed and the amino acid is coupled
 5. to the growing chain. This process is repeated until
 6. the full peptide is synthesized. The peptide is then
 7. purified and characterized. The peptide is then
 8. used in various experiments. The peptide is then
 9. used in various experiments. The peptide is then
 10. used in various experiments.

1. The first step in the synthesis of the peptide is the
 2. synthesis of the N-terminus. This is done by reacting
 3. the amino acid with a protecting group. The protecting
 4. group is then removed and the amino acid is coupled
 5. to the growing chain. This process is repeated until
 6. the full peptide is synthesized. The peptide is then
 7. purified and characterized. The peptide is then
 8. used in various experiments. The peptide is then
 9. used in various experiments. The peptide is then
 10. used in various experiments.

1. The first step in the synthesis of the peptide is the
 2. synthesis of the N-terminus. This is done by reacting
 3. the amino acid with a protecting group. The protecting
 4. group is then removed and the amino acid is coupled
 5. to the growing chain. This process is repeated until
 6. the full peptide is synthesized. The peptide is then
 7. purified and characterized. The peptide is then
 8. used in various experiments. The peptide is then
 9. used in various experiments. The peptide is then
 10. used in various experiments.

1. The first step in the synthesis of the peptide is the
 2. synthesis of the N-terminus. This is done by reacting
 3. the amino acid with a protecting group. The protecting
 4. group is then removed and the amino acid is coupled
 5. to the growing chain. This process is repeated until
 6. the full peptide is synthesized. The peptide is then
 7. purified and characterized. The peptide is then
 8. used in various experiments. The peptide is then
 9. used in various experiments. The peptide is then
 10. used in various experiments.

1. The first step in the synthesis of the peptide is the
 2. synthesis of the N-terminus. This is done by reacting
 3. the amino acid with a protecting group. The protecting
 4. group is then removed and the amino acid is coupled
 5. to the growing chain. This process is repeated until
 6. the full peptide is synthesized. The peptide is then
 7. purified and characterized. The peptide is then
 8. used in various experiments. The peptide is then
 9. used in various experiments. The peptide is then
 10. used in various experiments.

GenCore version 4.5
Copyright (c) 1993 - 2000 Compaq Inc.

OM protein - protein search, using sw model

Run on: September 13, 2002, 09:19:10 (with arguments)

4.0.4 MIP100 with updates/rev

Title: ILE-LEU-ARG-GLY

Perfect score: 19

Sequence: 1 ILPG 4

Scoring table: BLOSUM62

Gap: 10.0, Gapext 0.5

Searched: 747574 seqs, 11073796 residues

Total number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database	Accession	Score	Query Match	Length	DB ID	Description
1	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
2	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
3	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
4	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
5	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
6	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
7	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
8	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
9	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
10	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
11	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
12	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
13	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
14	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
15	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
16	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
17	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
18	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
19	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
20	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
21	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
22	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
23	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
24	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
25	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
26	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
27	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
28	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
29	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
30	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
31	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
32	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
33	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
34	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
35	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
36	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
37	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
38	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
39	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
40	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
41	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
42	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
43	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
44	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto
45	AAV87478	100.0	5	21	AAV87478	Anthrax yamamoto

pred. No. is the number of results pred. has a chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	100.0	5	21	AAV87478	Anthrax yamamoto
2	100.0	5	21	AAV87478	Anthrax yamamoto
3	100.0	5	21	AAV87478	Anthrax yamamoto
4	100.0	5	21	AAV87478	Anthrax yamamoto
5	100.0	5	21	AAV87478	Anthrax yamamoto
6	100.0	5	21	AAV87478	Anthrax yamamoto
7	100.0	5	21	AAV87478	Anthrax yamamoto
8	100.0	5	21	AAV87478	Anthrax yamamoto
9	100.0	5	21	AAV87478	Anthrax yamamoto
10	100.0	5	21	AAV87478	Anthrax yamamoto
11	100.0	5	21	AAV87478	Anthrax yamamoto
12	100.0	5	21	AAV87478	Anthrax yamamoto
13	100.0	5	21	AAV87478	Anthrax yamamoto
14	100.0	5	21	AAV87478	Anthrax yamamoto
15	100.0	5	21	AAV87478	Anthrax yamamoto
16	100.0	5	21	AAV87478	Anthrax yamamoto
17	100.0	5	21	AAV87478	Anthrax yamamoto
18	100.0	5	21	AAV87478	Anthrax yamamoto
19	100.0	5	21	AAV87478	Anthrax yamamoto
20	100.0	5	21	AAV87478	Anthrax yamamoto
21	100.0	5	21	AAV87478	Anthrax yamamoto
22	100.0	5	21	AAV87478	Anthrax yamamoto
23	100.0	5	21	AAV87478	Anthrax yamamoto
24	100.0	5	21	AAV87478	Anthrax yamamoto
25	100.0	5	21	AAV87478	Anthrax yamamoto
26	100.0	5	21	AAV87478	Anthrax yamamoto
27	100.0	5	21	AAV87478	Anthrax yamamoto
28	100.0	5	21	AAV87478	Anthrax yamamoto
29	100.0	5	21	AAV87478	Anthrax yamamoto
30	100.0	5	21	AAV87478	Anthrax yamamoto
31	100.0	5	21	AAV87478	Anthrax yamamoto
32	100.0	5	21	AAV87478	Anthrax yamamoto
33	100.0	5	21	AAV87478	Anthrax yamamoto
34	100.0	5	21	AAV87478	Anthrax yamamoto
35	100.0	5	21	AAV87478	Anthrax yamamoto
36	100.0	5	21	AAV87478	Anthrax yamamoto
37	100.0	5	21	AAV87478	Anthrax yamamoto
38	100.0	5	21	AAV87478	Anthrax yamamoto
39	100.0	5	21	AAV87478	Anthrax yamamoto
40	100.0	5	21	AAV87478	Anthrax yamamoto
41	100.0	5	21	AAV87478	Anthrax yamamoto
42	100.0	5	21	AAV87478	Anthrax yamamoto
43	100.0	5	21	AAV87478	Anthrax yamamoto
44	100.0	5	21	AAV87478	Anthrax yamamoto
45	100.0	5	21	AAV87478	Anthrax yamamoto

